跳转至内容
Merck
所有图片(1)

文件

28266

Sigma-Aldrich

Levofloxacin

98.0-102.0% anhydrous basis (HPLC)

别名:

(−)-Ofloxacin

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C18H20FN3O4
CAS号:
100986-85-4
分子量:
361.37
Beilstein:
7327015
MDL號碼:
MFCD00865049
分類程式碼代碼:
51102829
PubChem物質ID:
57648297
NACRES:
NA.85

生物源

synthetic

化驗

98.0-102.0% anhydrous basis (HPLC)

形狀

powder or crystals

顏色

light yellow-white to yellow-white

抗生素活性譜

Gram-negative bacteria
Gram-positive bacteria

作用方式

enzyme | inhibits

SMILES 字串

OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

InChI 密鑰

GSDSWSVVBLHKDQ-JTQLQIEISA-N

基因資訊

human ... KCNH1(3756)

正在寻找类似产品? 访问 产品对比指南

相关类别

應用

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic , antibiotic resistance , and resistance prevention studies. Antibiotic against bacterial respiratory tract infections.

生化／生理作用

Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

包裝

10mg, 1g, 10g

其他說明

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險聲明

H302,H317,H334

危險分類

Acute Tox. 4 Oral - Resp. Sens. 1A - Skin Sens. 1A

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Takeshi Hirano et al.
International journal of pharmaceutics, 351(1-2), 113-118 (2007-11-06)
L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner membrane followed by fatty acid beta-oxidation. It is known that members of the OCTN family play an important role in
Miriam Hurst et al.
Drugs, 62(14), 2127-2167 (2002-09-25)
Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less
George G Zhanel et al.
Drugs, 62(1), 13-59 (2002-01-16)
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still maintains the best in vitro activity
Gregory S Basarab et al.
Scientific reports, 5, 11827-11827 (2015-07-15)
With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea
M H Gotfried et al.
Chest, 119(4), 1114-1122 (2001-04-11)
To determine the steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Multiple-dose, open-label, randomized pharmacokinetic study. Thirty-six healthy, nonsmoking adult subjects were randomized either to oral levofloxacin, 500 or 750 mg once daily
查看所有相关文献

商品

Inhibition of Nucleic Acid Synthesis by Antibiotics

Quinolones are a key group of antibiotics that interfere with DNA synthesis by inhibiting topoisomerase, most frequently topoisomerase II (DNA gyrase), an enzyme involved in DNA replication.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门